<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397057</url>
  </required_header>
  <id_info>
    <org_study_id>1VIT14037</org_study_id>
    <nct_id>NCT02397057</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled Study to Investigate the Efficacy &amp; Safety of Injectafer in the Treatment of RLS</brief_title>
  <official_title>A Double-Blinded, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Restless Legs Syndrome (RLS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Regent, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Regent, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a Phase III, double blinded, multi-center, randomized, placebo-controlled study.&#xD;
      Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days&#xD;
      0 and 5. All treated subjects will be followed for efficacy and safety for 12 months. The&#xD;
      subject's participation in the study will be for approximately 1 year from Day 0.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase III, double blinded, multi-center, randomized, placebo-controlled study.&#xD;
      Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days&#xD;
      0 and 5. All treated subjects will be followed for efficacy and safety for 12 months.&#xD;
      Subjects will visit the clinic on Days 0 and 5 for treatment, and then on Days 14, 42, 168,&#xD;
      and 365. In between the clinic visits subjects will be contacted remotely on Days 84, 126,&#xD;
      210, 252, 294, and 336. The subject's participation in the study will be for approximately 1&#xD;
      year from Day 0.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Restless Legs Syndrome (IRLS) Total Score Change From Baseline on Day 42</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>Summary of the actual values of IRLS total score on baseline and Day 42, and the change from baseline to Day 42.&#xD;
Eligible subjects were to have met the following requirements prior to receiving additional treatment:&#xD;
A baseline score ≥ 15 on the International Restless Legs Syndrome (IRLS) Rating Scale. The minimum score is 15 with the maximum of 40. A score of less than 15 is not an indicator of RLS. However, a score of 15 or greater is an indicator of RLS. Further increase indicates more severe disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Patients Rated as Much or Very Much Improved With the Clinical Global Impression (CGI) Performed by Investigator (CGI-I)</measure>
    <time_frame>Day 42</time_frame>
    <description>Responder is defined as subjects rated as much or very much improved with the CGI-I on Day 42. Summary of the number (percentage) of CGI-I responder. Per the protocol, the he CGI is a 3-item observer-rated scale that measures illness severity (CGIS), global improvement or change (CGIC) and therapeutic response. The scale requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Improvement (CGI-S) by Subject</measure>
    <time_frame>Day 42</time_frame>
    <description>Similar to the CGI-I except this is self-reported, 7-item scale for assessment of symptoms after treatment with the rating as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restless Legs Syndrome Quality of Life (RLS-QLI) Change From Baseline to Day 42.</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>The Restless Legs Syndrome Quality of Life (RLS-QLI) instrument, a self-assessment, 17-item questionnaire with four scales identified through factor analysis: Daily Function, Social Function, Sleep Quality, and Emotional Well-Being, developed to facilitate clinical research on RLS. Scoring Instructions below:&#xD;
Social Function = Sum (Items 1, 2, 3, 4), subtract 4, divide by 16, multiply by 100&#xD;
Daily Function = Sum (Items 5, 6, 13,14, 15, 16), subtract 6, divide by 24, multiply by 100&#xD;
Sleep Quality = Sum (Item 7, 8, 9, 17), subtract 4, divide by 18, multiply by 100&#xD;
Emotional Well-being = Sum (Items 10, 11, 12), subtract 3, divide by 12, multiply by 100&#xD;
Note: Resulting scores range between 0-100.&#xD;
Higher scores on the RLS-QLI indicate a lower quality of life. Lower scores indicate a higher quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Linear Analog Scale Change From Baseline</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>The Fatigue Linear Analog Scale is a self-assessment scale in which a 100 mm line is used to measure the severity of fatigue and its effect on a person's activities and lifestyle. The scale severity measure ranges from No Fatigue to Worst Possible Fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcomes Study(MOS) Sleep Scale Change From Baseline to Day 42</measure>
    <time_frame>Change from Baseline and Day 42.</time_frame>
    <description>The MOS-Sleep scale, is a 12-item standardized, validated questionnaire for assessing sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache which has been demonstrated to be sensitive to RLS treatment effects. This questionnaire provides information about sleep quality. Individual questions can be used for analysis but summary or index scores of a group of questions, is more commonly used in analysis.&#xD;
The &quot;quantity of sleep&quot; dimension is the average number of hours of sleep per night reported by the patient and the &quot;optimal sleep&quot; is a dichotomized version that is &quot;yes&quot; when the number of hours of sleep is 7 or 8. The scores of the dimensions and of the sleep problem index were converted to a 0 to 100 scale, with higher scores reflecting more of the attribute implied by the name (e.g. greater sleep disturbance, greater adequacy of sleep).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Off Pre-Enrollment Prescribed Restless Legs Syndrome (RLS) Medications</measure>
    <time_frame>Time from Day 5 to Day 365</time_frame>
    <description>Subjects could start tapering off pre-enrollment prescribed RLS medications after Day 5 until Day 365.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">209</enrollment>
  <condition>Restless Legs Syndrome (RLS)</condition>
  <arm_group>
    <arm_group_label>Injectafer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV Placebo (15ml of Normal Saline) IV push at 2ml/minute</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injectafer</intervention_name>
    <arm_group_label>Injectafer</arm_group_label>
    <other_name>Ferinject®</other_name>
    <other_name>Iroprem®</other_name>
    <other_name>Renegy®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subject's ≥18 years of age, willing and able to give informed consent&#xD;
             to the study.&#xD;
&#xD;
          2. RLS symptoms affirming diagnosis. The IRLS Diagnostic Criteria must be met:&#xD;
&#xD;
               1. An urge (distressing need) to move the legs usually associated with painful or&#xD;
                  uncomfortable sensations in the legs. The urge to move may be present without the&#xD;
                  uncomfortable sensations. The arms or other body parts may be involved in&#xD;
                  addition to the legs.&#xD;
&#xD;
               2. The urge to move or unpleasant sensations are worse or exclusively present at&#xD;
                  rest or inactivity, such as lying down or sitting.&#xD;
&#xD;
               3. The urge to move or unpleasant sensations are partially/temporarily relieved with&#xD;
                  walking or moving the legs.&#xD;
&#xD;
               4. The urge to move or unpleasant sensations are worse in the evening or night than&#xD;
                  during the day or only occur in the evening or night. When symptoms are severe,&#xD;
                  the worsening at night may not be noticeable but must have been previously&#xD;
                  present.&#xD;
&#xD;
          3. Subjects should be on monotherapy for RLS. Treatment should be stable for at least 8&#xD;
             weeks prior to screening (See approved RLS Therapies/Regimen in Appendix III).&#xD;
&#xD;
          4. A score ≥15 on the IRLS Rating Scale at screening and on Day 0 prior to dosing.&#xD;
&#xD;
          5. Subjects on anti-depressants and sleep medications must be on a stable dose for at&#xD;
             least 6 months.&#xD;
&#xD;
          6. Subject has regular sleep hours between 9 pm and 9 am.&#xD;
&#xD;
          7. Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be&#xD;
             practicing an acceptable form of birth control: have had a hysterectomy or tubal&#xD;
             ligation, or otherwise be incapable of pregnancy, or have practiced any of the&#xD;
             following methods of contraception for at least one month prior to study entry:&#xD;
             hormonal contraceptives, spermicide with barrier, intrauterine device, or partner&#xD;
             sterility.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. RLS 2° to other disease or injury.&#xD;
&#xD;
          2. Disorders that require treatment with the same medications used for RLS include:&#xD;
             peripheral neuropathy and neurodegenerative disorders (i.e. Parkinson's Disease or&#xD;
             Dementia).&#xD;
&#xD;
          3. Stage 4 - 5 CKD, subjects on dialysis or anticipated to start dialysis while&#xD;
             participating in this study.&#xD;
&#xD;
          4. Any pain related (e.g., frequent muscle cramps, myalgia, fibromyalgia) or sleep&#xD;
             related disorders (e.g. sleep apnea, unless on stable Continuous Positive Airway&#xD;
             Pressure [CPAP]) which may confound the outcome measures.&#xD;
&#xD;
          5. Subjects with multiple sclerosis.&#xD;
&#xD;
          6. History of neuroleptic akathisia.&#xD;
&#xD;
          7. Parenteral iron use within 6 weeks prior to screening.&#xD;
&#xD;
          8. History of &gt;10 blood transfusions in the past 2 years.&#xD;
&#xD;
          9. Anticipated need for blood transfusion during the study.&#xD;
&#xD;
         10. Known hypersensitivity reaction to any component of Injectafer® (Ferric&#xD;
             Carboxymaltose).&#xD;
&#xD;
         11. Previously randomized to Injectafer® (FCM or VIT-45) in a clinical trial.&#xD;
&#xD;
         12. Current, active or acute or chronic infection other than viral upper respiratory tract&#xD;
             infection&#xD;
&#xD;
         13. Malignancy (other than basal or squamous cell skin cancer or the subject has been&#xD;
             cancer free for ≥ 5 years).&#xD;
&#xD;
         14. Pregnant or lactating women.&#xD;
&#xD;
         15. Seizure disorder currently being treated with medication.&#xD;
&#xD;
         16. Baseline ferritin ≥300 ng/mL.&#xD;
&#xD;
         17. Baseline TSAT ≥45%.&#xD;
&#xD;
         18. History of hemochromatosis, hemosiderosis, or other iron storage disorders.&#xD;
&#xD;
         19. AST or ALT greater than 2 times the upper limit of normal (ULN).&#xD;
&#xD;
         20. Hemoglobin greater than the ULN.&#xD;
&#xD;
         21. Known positive hepatitis B antigen (HBsAg), unless positive test can be attributed to&#xD;
             receipt of hepatitis B vaccination in childhood or hepatitis C viral antibody (HCV)&#xD;
             with evidence of active hepatitis (i.e., AST/ALT greater than the upper limit of&#xD;
             normal).&#xD;
&#xD;
         22. Known positive HIV-1/HIV-2 antibodies (anti-HIV).&#xD;
&#xD;
         23. Received an investigational drug within 30 days before randomization.&#xD;
&#xD;
         24. Chronic alcohol or drug abuse within the past 6 months.&#xD;
&#xD;
         25. Any other pre-existing laboratory abnormality, medical condition or disease, which per&#xD;
             the investigator may put the subject at risk if they participate in the study.&#xD;
&#xD;
         26. Subject unable or unwilling to comply with the study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Falone, MD</last_name>
    <role>Study Director</role>
    <affiliation>American Regent, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy San Diego</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Valley Research</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anderson Clinical Research</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Offices of South FL</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidAmmerica Neuroscience Institute</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66214-1505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Assoc., Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuromedical Clinical of Central Louisiana</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr for Brain &amp; Neuro Care, LLC</name>
      <address>
        <city>Fulton</city>
        <state>Maryland</state>
        <zip>20759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital, Sleep Disorders Clinical Research Program</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Neurology</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Center of Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guilford Neurologic Associates</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrolina Neurological Associates</name>
      <address>
        <city>Indian Land</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saad Upstate Neurology</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-State Mountain Neurology Associates</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Egret Bay Neurology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Polyclinic, Madison Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <results_first_submitted>November 2, 2020</results_first_submitted>
  <results_first_submitted_qc>October 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2021</results_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 2, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02397057/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02397057/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Injectafer</title>
          <description>Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.&#xD;
Injectafer</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline</title>
          <description>IV Placebo (15ml of Normal Saline) IV push at 2ml/minute&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105">Two Normal Saline participants received &quot;Injectafer&quot;. The data presented is considered accurate.</participants>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject did not receive study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One subject did not receive study drug and was excluded from the Safety and Full Analysis Set Populations.</population>
      <group_list>
        <group group_id="B1">
          <title>Injectafer</title>
          <description>Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.&#xD;
Injectafer</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline</title>
          <description>IV Placebo (15ml of Normal Saline) IV push at 2ml/minute&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="103"/>
            <count group_id="B3" value="208"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="12.31"/>
                    <measurement group_id="B2" value="56.9" spread="13.73"/>
                    <measurement group_id="B3" value="57.6" spread="13.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>One subject did not receive study drug and was excluded from the safety and full analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>One subject did not receive study drug and was excluded from the safety and full analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>One subject did not receive study drug and was excluded from the safety and full analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.6" spread="9.4"/>
                    <measurement group_id="B2" value="167" spread="9.4"/>
                    <measurement group_id="B3" value="167.3" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.8" spread="21.4"/>
                    <measurement group_id="B2" value="79.1" spread="20.8"/>
                    <measurement group_id="B3" value="81" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Iron intolerance</title>
          <population>One subject did not receive study drug and was excluded from the safety and full analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>RLS Medication-Related Augmentation</title>
          <population>One participate did not receive study drug and was excluded from the safety and full analysis set population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No augmentation</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Uncertain augmentation</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Definitive augmentation</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>International Restless Legs Syndrome (IRLS) Total Score Change From Baseline on Day 42</title>
        <description>Summary of the actual values of IRLS total score on baseline and Day 42, and the change from baseline to Day 42.&#xD;
Eligible subjects were to have met the following requirements prior to receiving additional treatment:&#xD;
A baseline score ≥ 15 on the International Restless Legs Syndrome (IRLS) Rating Scale. The minimum score is 15 with the maximum of 40. A score of less than 15 is not an indicator of RLS. However, a score of 15 or greater is an indicator of RLS. Further increase indicates more severe disease.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>One subject did not receive study drug and was excluded from the safety and Full analysis set population.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>IV Placebo (15ml of Normal Saline) IV push at 2ml/minute&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>International Restless Legs Syndrome (IRLS) Total Score Change From Baseline on Day 42</title>
          <description>Summary of the actual values of IRLS total score on baseline and Day 42, and the change from baseline to Day 42.&#xD;
Eligible subjects were to have met the following requirements prior to receiving additional treatment:&#xD;
A baseline score ≥ 15 on the International Restless Legs Syndrome (IRLS) Rating Scale. The minimum score is 15 with the maximum of 40. A score of less than 15 is not an indicator of RLS. However, a score of 15 or greater is an indicator of RLS. Further increase indicates more severe disease.</description>
          <population>One subject did not receive study drug and was excluded from the safety and Full analysis set population.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="6.27"/>
                    <measurement group_id="O2" value="24.5" spread="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="8.69"/>
                    <measurement group_id="O2" value="18.7" spread="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="8.44"/>
                    <measurement group_id="O2" value="-5.9" spread="9.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Rated as Much or Very Much Improved With the Clinical Global Impression (CGI) Performed by Investigator (CGI-I)</title>
        <description>Responder is defined as subjects rated as much or very much improved with the CGI-I on Day 42. Summary of the number (percentage) of CGI-I responder. Per the protocol, the he CGI is a 3-item observer-rated scale that measures illness severity (CGIS), global improvement or change (CGIC) and therapeutic response. The scale requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.</description>
        <time_frame>Day 42</time_frame>
        <population>Responder(a), n/m(b) : a : Responder was defined as subjects rated as much or very much improved with the CGI-I.&#xD;
b : n is the number of responders; m is number of subjects who had non-missing results at the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>IV Placebo (15ml of Normal Saline) IV push at 2ml/minute&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Rated as Much or Very Much Improved With the Clinical Global Impression (CGI) Performed by Investigator (CGI-I)</title>
          <description>Responder is defined as subjects rated as much or very much improved with the CGI-I on Day 42. Summary of the number (percentage) of CGI-I responder. Per the protocol, the he CGI is a 3-item observer-rated scale that measures illness severity (CGIS), global improvement or change (CGIC) and therapeutic response. The scale requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.</description>
          <population>Responder(a), n/m(b) : a : Responder was defined as subjects rated as much or very much improved with the CGI-I.&#xD;
b : n is the number of responders; m is number of subjects who had non-missing results at the visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Observed cases, logistic regression analysis. Subjects with missing data on Day 42 were excluded from the statistical testing.</non_inferiority_desc>
            <p_value>0.3690</p_value>
            <p_value_desc>p-value was estimated by logistic regression with treatment, region (US, EUR), and baseline RLS medication-related augmentation as fixed factors, and baseline IRLS as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression-Improvement (CGI-S) by Subject</title>
        <description>Similar to the CGI-I except this is self-reported, 7-item scale for assessment of symptoms after treatment with the rating as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.</description>
        <time_frame>Day 42</time_frame>
        <population>Observed cases (n/m(a) [%])&#xD;
a: n is the number of subjects of the category, m is number of subjects who have non-missing results at the visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>IV Placebo (15ml of Normal Saline) IV push at 2ml/minute&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression-Improvement (CGI-S) by Subject</title>
          <description>Similar to the CGI-I except this is self-reported, 7-item scale for assessment of symptoms after treatment with the rating as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.</description>
          <population>Observed cases (n/m(a) [%])&#xD;
a: n is the number of subjects of the category, m is number of subjects who have non-missing results at the visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Restless Legs Syndrome Quality of Life (RLS-QLI) Change From Baseline to Day 42.</title>
        <description>The Restless Legs Syndrome Quality of Life (RLS-QLI) instrument, a self-assessment, 17-item questionnaire with four scales identified through factor analysis: Daily Function, Social Function, Sleep Quality, and Emotional Well-Being, developed to facilitate clinical research on RLS. Scoring Instructions below:&#xD;
Social Function = Sum (Items 1, 2, 3, 4), subtract 4, divide by 16, multiply by 100&#xD;
Daily Function = Sum (Items 5, 6, 13,14, 15, 16), subtract 6, divide by 24, multiply by 100&#xD;
Sleep Quality = Sum (Item 7, 8, 9, 17), subtract 4, divide by 18, multiply by 100&#xD;
Emotional Well-being = Sum (Items 10, 11, 12), subtract 3, divide by 12, multiply by 100&#xD;
Note: Resulting scores range between 0-100.&#xD;
Higher scores on the RLS-QLI indicate a lower quality of life. Lower scores indicate a higher quality of life.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>One subject did not receive study drug and was excluded from the Safety and Full Analysis Set Populations.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>IV Placebo (15ml of Normal Saline) IV push at 2ml/minute&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Restless Legs Syndrome Quality of Life (RLS-QLI) Change From Baseline to Day 42.</title>
          <description>The Restless Legs Syndrome Quality of Life (RLS-QLI) instrument, a self-assessment, 17-item questionnaire with four scales identified through factor analysis: Daily Function, Social Function, Sleep Quality, and Emotional Well-Being, developed to facilitate clinical research on RLS. Scoring Instructions below:&#xD;
Social Function = Sum (Items 1, 2, 3, 4), subtract 4, divide by 16, multiply by 100&#xD;
Daily Function = Sum (Items 5, 6, 13,14, 15, 16), subtract 6, divide by 24, multiply by 100&#xD;
Sleep Quality = Sum (Item 7, 8, 9, 17), subtract 4, divide by 18, multiply by 100&#xD;
Emotional Well-being = Sum (Items 10, 11, 12), subtract 3, divide by 12, multiply by 100&#xD;
Note: Resulting scores range between 0-100.&#xD;
Higher scores on the RLS-QLI indicate a lower quality of life. Lower scores indicate a higher quality of life.</description>
          <population>One subject did not receive study drug and was excluded from the Safety and Full Analysis Set Populations.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" spread="15.0"/>
                    <measurement group_id="O2" value="54.3" spread="13.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2" spread="15.49"/>
                    <measurement group_id="O2" value="62.8" spread="14.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="12.48"/>
                    <measurement group_id="O2" value="8.7" spread="14.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue Linear Analog Scale Change From Baseline</title>
        <description>The Fatigue Linear Analog Scale is a self-assessment scale in which a 100 mm line is used to measure the severity of fatigue and its effect on a person's activities and lifestyle. The scale severity measure ranges from No Fatigue to Worst Possible Fatigue.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>One subject did not receive study drug and was excluded from the Safety and Full Analysis Set Populations.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>IV Placebo (15ml of Normal Saline) IV push at 2ml/minute&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue Linear Analog Scale Change From Baseline</title>
          <description>The Fatigue Linear Analog Scale is a self-assessment scale in which a 100 mm line is used to measure the severity of fatigue and its effect on a person's activities and lifestyle. The scale severity measure ranges from No Fatigue to Worst Possible Fatigue.</description>
          <population>One subject did not receive study drug and was excluded from the Safety and Full Analysis Set Populations.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.78" spread="26.32"/>
                    <measurement group_id="O2" value="57.34" spread="23.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.90" spread="26.25"/>
                    <measurement group_id="O2" value="42.57" spread="27.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.98" spread="27.55"/>
                    <measurement group_id="O2" value="-16.50" spread="28.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Outcomes Study(MOS) Sleep Scale Change From Baseline to Day 42</title>
        <description>The MOS-Sleep scale, is a 12-item standardized, validated questionnaire for assessing sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache which has been demonstrated to be sensitive to RLS treatment effects. This questionnaire provides information about sleep quality. Individual questions can be used for analysis but summary or index scores of a group of questions, is more commonly used in analysis.&#xD;
The &quot;quantity of sleep&quot; dimension is the average number of hours of sleep per night reported by the patient and the &quot;optimal sleep&quot; is a dichotomized version that is &quot;yes&quot; when the number of hours of sleep is 7 or 8. The scores of the dimensions and of the sleep problem index were converted to a 0 to 100 scale, with higher scores reflecting more of the attribute implied by the name (e.g. greater sleep disturbance, greater adequacy of sleep).</description>
        <time_frame>Change from Baseline and Day 42.</time_frame>
        <population>Only participants with Sleep disturbance are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>IV Placebo (15ml of Normal Saline) IV push at 2ml/minute&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Outcomes Study(MOS) Sleep Scale Change From Baseline to Day 42</title>
          <description>The MOS-Sleep scale, is a 12-item standardized, validated questionnaire for assessing sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache which has been demonstrated to be sensitive to RLS treatment effects. This questionnaire provides information about sleep quality. Individual questions can be used for analysis but summary or index scores of a group of questions, is more commonly used in analysis.&#xD;
The &quot;quantity of sleep&quot; dimension is the average number of hours of sleep per night reported by the patient and the &quot;optimal sleep&quot; is a dichotomized version that is &quot;yes&quot; when the number of hours of sleep is 7 or 8. The scores of the dimensions and of the sleep problem index were converted to a 0 to 100 scale, with higher scores reflecting more of the attribute implied by the name (e.g. greater sleep disturbance, greater adequacy of sleep).</description>
          <population>Only participants with Sleep disturbance are included.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.086" spread="1.829"/>
                    <measurement group_id="O2" value="-9.015" spread="1.902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LOCF, ANCOVA Analysis</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1108</p_value>
            <method>ANCOVA</method>
            <param_type>Least square(LS) mean difference</param_type>
            <param_value>-4.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.542</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.083</ci_lower_limit>
            <ci_upper_limit>0.941</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Off Pre-Enrollment Prescribed Restless Legs Syndrome (RLS) Medications</title>
        <description>Subjects could start tapering off pre-enrollment prescribed RLS medications after Day 5 until Day 365.</description>
        <time_frame>Time from Day 5 to Day 365</time_frame>
        <population>Full Analysis Set Population. Subjects who discontinued or completed the study before an intervention were censored at the last study visit.&#xD;
Subjects Receiving RLS Intervention after Day 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Injectafer</title>
            <description>Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.&#xD;
Injectafer</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>IV Placebo (15ml of Normal Saline) IV push at 2ml/minute&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time Off Pre-Enrollment Prescribed Restless Legs Syndrome (RLS) Medications</title>
          <description>Subjects could start tapering off pre-enrollment prescribed RLS medications after Day 5 until Day 365.</description>
          <population>Full Analysis Set Population. Subjects who discontinued or completed the study before an intervention were censored at the last study visit.&#xD;
Subjects Receiving RLS Intervention after Day 5.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="34" upper_limit="164"/>
                    <measurement group_id="O2" value="61" lower_limit="61" upper_limit="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>p-value was estimated using continuity-corrected chi-square test.</p_value_desc>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, I month</time_frame>
      <desc>209 participants were randomized of whom 208 received study drug: 105 who were randomized to Injectafer and 103 who were randomized to placebo. Two participants randomized to Placebo received Injectafer. Therefore the Numbers at Risk comprised 107 for Injectafer 101 for placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>Injectafer</title>
          <description>Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.&#xD;
Injectafer</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline</title>
          <description>IV Placebo (15ml of Normal Saline) IV push at 2ml/minute&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer stage IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Gamma-Glutamyl Transferase Increase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark A. Falone, MD MPH</name_or_title>
      <organization>American Regent, Inc</organization>
      <phone>6317723544 ext 61844</phone>
      <email>mfalone@americanregent.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

